Moberg Pharma AB (publ) (MOB.ST)
SEK 7.84
(-0.19%)
SEK 7.84
(-0.19%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 24 Million SEK | -22.15% |
| 2022 | 30.83 Million SEK | 83.15% |
| 2021 | 16.83 Million SEK | -80.19% |
| 2020 | 85 Million SEK | 0.0% |
| 2018 | 657.59 Million SEK | -1.98% |
| 2017 | 670.84 Million SEK | 0.04% |
| 2016 | 670.55 Million SEK | 1402.43% |
| 2015 | 44.63 Million SEK | -20.26% |
| 2014 | 55.97 Million SEK | -20.17% |
| 2013 | 70.11 Million SEK | -31.61% |
| 2012 | 102.52 Million SEK | 554.46% |
| 2011 | 15.66 Million SEK | 33.96% |
| 2010 | 11.69 Million SEK | 129.85% |
| 2009 | 5.08 Million SEK | -30.83% |
| 2008 | 7.35 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 27.18 Million SEK | 13.22% |
| 2024 Q2 | 30.54 Million SEK | 12.38% |
| 2023 Q2 | 23.95 Million SEK | 7.84% |
| 2023 Q3 | 27.42 Million SEK | 14.45% |
| 2023 Q4 | 24 Million SEK | -12.45% |
| 2023 FY | 24 Million SEK | -22.15% |
| 2023 Q1 | 22.21 Million SEK | -27.96% |
| 2022 Q3 | 13.64 Million SEK | -11.89% |
| 2022 FY | 30.83 Million SEK | 83.15% |
| 2022 Q4 | 30.83 Million SEK | 125.98% |
| 2022 Q1 | 14.05 Million SEK | -16.54% |
| 2022 Q2 | 15.48 Million SEK | 10.22% |
| 2021 Q2 | 15.39 Million SEK | -14.88% |
| 2021 Q4 | 16.83 Million SEK | 6.39% |
| 2021 FY | 16.83 Million SEK | -80.19% |
| 2021 Q1 | 18.08 Million SEK | -78.5% |
| 2021 Q3 | 15.82 Million SEK | 2.8% |
| 2020 Q3 | 31.63 Million SEK | 0.0% |
| 2020 Q1 | 36.65 Million SEK | 19.35% |
| 2020 FY | 85 Million SEK | 0.0% |
| 2020 Q4 | 84.12 Million SEK | 165.9% |
| 2019 Q4 | 30.71 Million SEK | -44.64% |
| 2019 Q1 | 765.17 Million SEK | 16.36% |
| 2019 Q2 | 88.94 Million SEK | -88.38% |
| 2019 Q3 | 55.47 Million SEK | -37.63% |
| 2018 Q2 | 685.08 Million SEK | 3.71% |
| 2018 FY | 657.59 Million SEK | -1.98% |
| 2018 Q4 | 657.59 Million SEK | -1.42% |
| 2018 Q3 | 667.04 Million SEK | -2.63% |
| 2018 Q1 | 660.57 Million SEK | -1.53% |
| 2017 Q2 | 676.04 Million SEK | 0.61% |
| 2017 Q1 | 671.91 Million SEK | 0.2% |
| 2017 FY | 670.84 Million SEK | 0.04% |
| 2017 Q4 | 670.84 Million SEK | 2.35% |
| 2017 Q3 | 655.43 Million SEK | -3.05% |
| 2016 Q2 | 345.48 Million SEK | 0.4% |
| 2016 Q3 | 438.5 Million SEK | 26.93% |
| 2016 Q4 | 670.55 Million SEK | 52.92% |
| 2016 FY | 670.55 Million SEK | 1402.43% |
| 2016 Q1 | 344.11 Million SEK | 671.02% |
| 2015 Q4 | 44.63 Million SEK | -25.09% |
| 2015 Q3 | 59.58 Million SEK | -30.62% |
| 2015 FY | 44.63 Million SEK | -20.26% |
| 2015 Q1 | 70.44 Million SEK | 25.87% |
| 2015 Q2 | 85.87 Million SEK | 21.89% |
| 2014 Q4 | 55.97 Million SEK | -6.15% |
| 2014 Q3 | 59.63 Million SEK | -31.34% |
| 2014 Q1 | 74.43 Million SEK | 6.16% |
| 2014 Q2 | 86.85 Million SEK | 16.68% |
| 2014 FY | 55.97 Million SEK | -20.17% |
| 2013 Q1 | 89.64 Million SEK | -12.56% |
| 2013 Q3 | 75.08 Million SEK | -15.08% |
| 2013 FY | 70.11 Million SEK | -31.61% |
| 2013 Q4 | 70.11 Million SEK | -6.62% |
| 2013 Q2 | 88.41 Million SEK | -1.37% |
| 2012 Q4 | 102.52 Million SEK | 418.29% |
| 2012 FY | 102.52 Million SEK | 554.46% |
| 2012 Q3 | 19.78 Million SEK | 2.44% |
| 2012 Q2 | 19.31 Million SEK | 9.93% |
| 2012 Q1 | 17.56 Million SEK | 12.13% |
| 2011 FY | 15.66 Million SEK | 33.96% |
| 2011 Q2 | 11.34 Million SEK | -6.31% |
| 2011 Q4 | 15.66 Million SEK | 32.82% |
| 2011 Q3 | 11.79 Million SEK | 3.98% |
| 2011 Q1 | 12.1 Million SEK | 3.53% |
| 2010 FY | 11.69 Million SEK | 129.85% |
| 2010 Q4 | 11.69 Million SEK | 0.0% |
| 2009 FY | 5.08 Million SEK | -30.83% |
| 2008 FY | 7.35 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AcuCort AB | 10.97 Million SEK | -118.743% |
| AlzeCure Pharma AB (publ) | 8.22 Million SEK | -191.807% |
| BioGaia AB (publ) | 302.84 Million SEK | 92.073% |
| Enzymatica AB (publ) | 49.3 Million SEK | 51.306% |
| Enorama Pharma AB (publ) | 14.84 Million SEK | -61.696% |
| Gabather AB (publ) | 6.87 Million SEK | -249.04% |
| Klaria Pharma Holding AB (publ.) | 31.98 Million SEK | 24.945% |
| Nanexa AB (publ) | 36.42 Million SEK | 34.096% |
| Newbury Pharmaceuticals AB (publ) | 38.95 Million SEK | 38.371% |
| ODI Pharma AB | 10.05 Million SEK | -138.693% |
| Orexo AB (publ) | 727.7 Million SEK | 96.701% |
| Probi AB (publ) | 181.31 Million SEK | 86.76% |
| Swedencare AB (publ) | 2.31 Billion SEK | 98.963% |
| Swedish Orphan Biovitrum AB (publ) | 40.16 Billion SEK | 99.94% |
| Toleranzia AB | 6.9 Million SEK | -247.474% |
| Vivesto AB | 30.45 Million SEK | 21.164% |